Phosphorylated Smad2 in Advanced Stage Gastric Carcinoma

BMC Cancer

Research Article

Satoru Noda¹  Tetsuji Sawada¹  Ryoji Kaizaki¹  Hiroaki Tanaka¹  Taro Matsuzaki¹  Osamu Shinto¹  Naoshi Kubo¹  Masaichi Ohira¹  Kazuya Muguruma¹  Yosuke Doi¹  Takahiro Toyokawa¹  Takafumi Nishii¹  Kosei Hirakawa¹  Masakazu Yashiro² 

[1] Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan;Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan;Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, Japan;

关键词: Gastric Cancer;    Esophageal Squamous Cell Carcinoma;    Gastric Carcinoma;    Peritoneal Metastasis;    Tubular Adenocarcinoma;   

DOI  :  10.1186/1471-2407-10-652

 received in 2010-04-11, accepted in 2010-11-26,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundTransforming growth factor β (TGFβ) receptor signaling is closely associated with the invasion ability of gastric cancer cells. Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma. The aim of the current study is to clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages.MethodsImmunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens from 135 patients with advanced gastric adenocarcinomas. We also evaluated the relationship between the expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas.ResultsThe p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas. The p-Smad2 expression level was significantly higher in diffuse type carcinoma (p = 0.007), tumours with peritoneal metastasis (p = 0.017), and tumours with lymph node metastasis (p = 0.047). The prognosis for p-Smad2-high patients was significantly (p = 0.035, log-rank) poorer than that of p-Smad2-low patients, while a multivariate analysis revealed that p-Smad2 expression was not an independence prognostic factor.ConclusionThe expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.

【 授权许可】

Unknown   
© Shinto et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.